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CARDIORENAL RESPONSE TO NEUTML ENDOPEPTIDASE 
INHIBITION IN ACUTE CONGESTIVE HEART FAILURE. 
Seymour, Ph.D., Norma Delaney, 
, M.D., Mayo Clinic, Rochester, 
MN and Squibb Medical Research Institute, Princeton, NJ. 
Neutral endopeptidase inhibition (NEP9 has been proposed F a 
therapeutic modality in congestive heartfailun (CHF) by prevenhng 
the degradation of atrial nabiuretic factor (ANP). The effect of 
NEPI on ANP degradation may promote the actions of ANF_ by 
increasing systemic concenlralions or enhancing local peptide acaon. 
The current study was designed to investigate the action of NEPI 
(SO 28.603) uuon cardiorenal function in acute experimental CHF 
~r&iucitd gy -rapid right ventricular pacing in two groups of 
anesthetized dogs, CHF pIus NEPI (60 q/kg IV, n4) versus 
CHF control (n=4). In the CHF+NEPI group as compared 10 CHP 
alone, a si i&tit differential cardiore~d kponse. tias observed 
following %P I administration depicted by an increase in CO (+ 
0,16 f 0.12 versus - 0.26 f 0.07 L&nin, pcO.05). decrease in RA 
pressure (- 0.4 f 0.1 versus + 0.5 f 0.3 aunHg, p&.05), and an 
Increase in urinary sodium excretion (+ 25.23 + 10.68 versus - 
24.24 f 11.35 win, p<o.OS). These cardiorenal actions of 
NEPI in CHP, were not associated with increases in elevated 
endogenous plasma ANF levels (487 f 83 to 498 f 82 pg/ml, NS). 
The lack of increase in plasma ANF may however be mediated by a 
decrease in endogenous ANF secretion due to a decrease in atrial 
pressure. This study demonstrates for the fast time the beneficial 
actions of NEPI in acute CHF to enhance cardionnal function. 
NEUROPEPTIDE Y IN THE FAILING VENTRICLE OF PATIENTS WITH 
IDIOPATHIC DIIATED CARDIONYOPATHY 
LACK OF INCREASED RESPONSIVENESS TO j?+STIfjULATION 
AFTER LONG-TERM fit-PARTIAL GONIST THERAPY. 
, J. David Port, B.S., Michael 
R. Bristow, M.D., 
Kralios, N.D., 
Ph.D., Ray E. Hershberger, N.D., Alex 
Ph.D., Glen Hanson, D.D.S., Ph.D.. 
University of Utah, Salt Lake City, Utah 
Increased adrenergic activity may be an important patho- 
physiologic mechanism in patients wieh heart failure. We 
investigated the possibility that neuropeptide Y (NPY), a 
36-amino acid peptide that coexists in the adrenergic 
neuron with norepinephrine (NE),, is altered by heart 
failure. NPY was measured by radioimmunoassay in 
ventricles from patientn undergoing cardiac eransplanta- 
tion due to idiopathic caroiolnyopathy (IDC) and compared 
to nonfailing (NF) tissue from organ donors whose hearts 
were not used for transplantation. The data are strati- 
fied according to preoperative use of IV inotropes includ- 
ing dopamine (DA) plus dobutamine (DBT) or DBT alone. 
IDC (no inotropes) 
IDC (DBT) 
IDC (DA+DBT) 
*p<O. 05 compared to NF, 
inotropes). 
**p(O.OS compared to IDC (no 
Conclusion: NPY is significantly decreased in IDC 
compared to NF hearts. Additionally, the indirect acting 
agonist DA reduced NPY further presumably by increasing 
release, whereas DBT alone does not. NPY may serVe as a 
marker of adrenergic activity and of NE release in 
patients with IDC. The potential effect of NPY release on 
coronary vasomotor tone and myocardial contractility 
remain to be determined. 
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Cschexia is a characteristic finding in patients (pts) with end-s@e 
hesti failure, but its cause remains unknown. Tumor necrosis factor has been 
recently implicated in the pathogenesis of cschexia in pts with cancer and 
chronic infections, but its role in cardiovascular disease has not been 
defined. We measured serum levels of tumor necrosis factor (TTW in 25 
patients with CHF and in 19 healthy controls. TNF was measured by a 
bioassay based on in vitro cytotoxicity against L.929 cells. 
Levels of TNF welp higher in CHF pts than in the controls (127 f 30 
vs11*4U/ml,p<0.001. AmongthecHFpts,9 
pressure (MAP, mm Hg), LV filling pressure 
vascular resistance (SVR, d-s-c), plasma renin activity (PRA, ng/rnl/hr), 
plasma norepinephrine UNfZ, pg/mU and serum creatinine (Cr, mg/dl). All 
variables were measured while pts were receiving only digitalis and 
diuretics. Results are shown below, where * = D c 0.05 (low vs hinh): . 
Q 
Low’INF 17 2.2 83 26 1540 1.6 782 1.1 
High TNF 18 2.1 88 27 1780 9.6” 623 1.7, 
The high- and low-TNF groups were similar with respect to the cause 
of CHF and all hemodynsmic variables. High-TNF pts, however, had 
higher PRA and Cr (but not PNE) than low-TNF pts. Only one of the 7 pts 
with a PRA < 2 ng/ml/hr (but all 11 pts with a PRA > 5 ng/ml/hr) had 
TNF levels > 40 U/ml. Interestingly, body weight was lower in the high- 
‘INF than in the low-TNF group (85 f 4% vs 97 f 3% of ideal), p c 0.05. 
These data indicate that circulating levels of TNF are increased in 
patients with end-stage CHF, particularly those with cachexia, renal 
dysfunctionand marked activation of the renin-angiolensinsystem. 
Michel F. Rousseau. M.D., F.A.C.C., Jean Etienne, Henri 
Van Mechelen, Oliwier Gurn4, M.D., Hubert Pouleur, 
M.D., F.A.C.C. University 
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of Louvain, Brussels, 
In heart failure (HF), long-term etoprolol dosing 
improves LV response to j-stimulation. To determine if 
this occurred with xamoterol (X), a fli-adrenoceotor 
partial agonist, 
function 
6 pts with t#-and a depressed LV 
(ejection fraction. EF: 30&3X) and 5 Dts with _ 
preserved l!F-(6028%) were studied. LV finction \MFllar) 
was assessed at baseline (Bl) and after 3 months of 
oral X dosing (Xl, 200 mg b.i.d.). X treatment was 
continued for 51517 months (range 12-72) before being 
stopped for 3 days to obtain new baseline data (82). 
The response to X was again determined using i.v. 
infusio;R(200L;f{Fg, X2). *P<O.O5 ws Bl, 5PcO.05 vs 82. 
bpm mmHg 
LVSP (dP/d;)(DPbo _ 
ft; 
72~3 25$3 
mmHg 
132k7 2oi2 
7723 1%2* 12829 26~2~ 
!; 
74t5 2022 13829 2122 
7423 15*3*9 13239 2512*5 57145 
After 1 to 6 years of dosing, X still reduced LVEDP and 
improved the indices of inotropic state (dP/dt)/DRo 
and of relaxation Tl to the same extent as after 3 
months of therapy. Further, the dose-response 
relationships were similar in pts with preserved or 
depressed EF. Thus, tachyphylaxis did not occur with X 
but there was no evidence of an increased response to 
&-stimulation in pts with HF, suggesting that X is 
unable to induce fll-receptor up-regulation. 
